Business Wire

WittKieffer Life Sciences Practice Expands Global Capabilities

Share

WittKieffer, a leading global executive search and advisory firm dedicated to improving quality of life through impactful leadership, today announced the expansion of its global Life Sciences Practice with the addition of three experienced consultants.

WittKieffer is pleased to welcome Susan Oliver and Luigi Frezza, who join WittKieffer’s growing practice as Managing Directors, as well as Hannah Scarisbrick, who will serve as a Senior Consultant. The Life Sciences Practice works collaboratively around the world, drawing on its consultants’ diverse experiences to place innovative, visionary and highly agile executives at pharmaceutical, biopharma, medical device, diagnostic and other life sciences companies. Oliver is based in Orlando, Fla., while Frezza and Scarisbrick will serve clients out of London.

“For more than 50 years, WittKieffer has operated exclusively at the intersection of science, healthcare delivery, and education—the Quality of Life ecosystem,” said Andrew Chastain, Chief Executive Officer of WittKieffer. “Today's announcement is the latest step forward in our multi-pronged investment in serving that ecosystem via impactful leadership. The life sciences sector, from early-stage biotech to mature pharma services, is incredibly dynamic. In addition to our specific expertise in this sector, WittKieffer brings a multi-dimensional perspective to understanding how life sciences intersects academic medicine, healthcare systems and providers of care and wellness.”

The experience and credentials of the three new individuals to the WittKieffer practice include:

  • Susan Oliver, a Managing Director in the global Life Sciences Practice, has a long and successful track record in the retained executive search profession, including more than 25 years' experience, with more than half of that as a senior client-facing consultant. Her expertise ranges across biotech, pharmaceutical and medical technology companies, with particular knowledge of early stage and clinical stage venture-backed companies.
  • Luigi Frezza, a Managing Director in the global Life Sciences Practice, has over 15 years' experience in executive search. He is an expert in conducting international recruiting engagements across multiple life sciences functions in Europe and the U.S.—from senior roles in research and development, to technical and commercial operations, and a broad range of corporate functional roles.
  • Hannah Scarisbrick, a Consultant in the global Life Sciences Practice, is an experienced executive search consultant who brings execution and business development capacity to the practice and the firm’s London office. Hannah has expertise in working with clients to find transformational leaders who can meet their current and future strategic needs.

“Susan, Luigi and Hannah bring decades of experience across markets and sectors and are tremendous additions to our team,” said Morten Nielsen, Global Practice Leader of Life Sciences at WittKieffer. “Working globally is part of our DNA. Their addition to the team expands our capabilities to partner with clients throughout the world and gain unrestricted access to executive talent across the life sciences sector.”

Today’s announcement illustrates WittKieffer’s commitment to serving for-profit and investor-backed life science and healthcare companies that are transforming lives and creating value for their owners, teams, customers and communities. To learn more about WittKieffer’s Life Sciences Practice, visit wittkieffer.com/practices/life-sciences.

About WittKieffer

WittKieffer is a leading global executive search and advisory firm dedicated to improving quality of life through impactful leadership. For more than 50 years, the firm has operated exclusively at the intersection of for-profit and not-for-profit healthcare delivery, science, and education–the “Quality of Life” ecosystem. Through its DEI, Interim Leadership, Board Services and Leadership Advisory solutions, WittKieffer helps build and enhance leadership teams that transform organizations and communities. WittKieffer combines the agility and personalized service of a boutique firm with global scale to deliver exceptional outcomes. Visit wittkieffer.com to learn more.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Adam Wise
(715) 213-9170
awise@kwtglobal.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Ipsen to Acquire Epizyme, Expanding Its Portfolio in Oncology27.6.2022 07:00:00 CEST | Press release

Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220626005092/en/ Disclaimer: Intended for international media and investor audiences only Ipsen (Euronext: IPN; ADR: IPSEY) and Epizyme (Nasdaq: EPZM) today announced that they have entered into a definitive merger agreement under which Ipsen will acquire Epizyme. The transaction was unanimously approved by both Ipsen and Epizyme Boards of Directors and is anticipated to close by the end of the third quarter of 2022, subject to the satisfaction of all closing conditions. Epizyme is a fully integrated, commercial-stage biopharmaceutical company developing and delivering transformative therapies against novel epigenetic targets for cancer patients. The primary focus of the acquisition is on the lead medicine, Tazverik® (tazemetostat), a first-in-class, chemotherapy-free EZH2a inhibitor, which was granted Accelerated Approval by the U.S. Food and Drug Administratio

The Group Announces the Beginning of An Open-Ended Share Repurchase Programme Of Prosus And Naspers Shares27.6.2022 06:00:00 CEST | Press release

The board of directors of Naspers Limited ("Naspers Board") (JSE: NPN; LSE: NPSN) and board of directors ("Prosus Board") of Prosus N.V. ("Prosus") (Euronext Amsterdam: PRX; JSE: PRX) are pleased to announce the beginning of an open-ended, repurchase programme in respect of the ordinary shares N in the capital of Prosus ("Prosus Shares") and N ordinary shares ("Naspers Shares") in the share capital of Naspers, from the respective Prosus and Naspers (together the "Group") free-float shareholders (together the "Repurchase Programme"). The Repurchase Programme is expected to efficiently unlock immediate value for the shareholders of Prosus ("Prosus Shareholders") and Naspers ("Naspers Shareholders"). Prosus will begin selling small numbers of ordinary shares in Tencent Holdings Limited (“Tencent”) held by the Group (“Tencent Shares”) regularly and in an orderly manner, while concurrently purchasing Prosus Shares and Naspers Shares pursuant to the Repurchase Programme, as long as the Group

The Group Announces the Beginning of an Open-Ended Share Repurchase Programme of Prosus and Naspers Shares27.6.2022 06:00:00 CEST | Press release

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, INTO OR IN ANY JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE PROHIBITED BY APPLICABLE LAW. PLEASE SEE THE IMPORTANT NOTICE AND DISCLAIMERS AT THE END OF THIS ANNOUNCEMENT. The board of directors of Naspers Limited ("Naspers Board") (JSE: NPN; LSE: NPSN) and board of directors ("Prosus Board") of Prosus N.V. ("Prosus") (Euronext Amsterdam: PRX; JSE: PRX) are pleased to announce the beginning of an open-ended, repurchase programme in respect of the ordinary shares N in the capital of Prosus ("Prosus Shares") and N ordinary shares ("Naspers Shares") in the share capital of Naspers, from the respective Prosus and Naspers (together the "Group") free-float shareholders (together the "Repurchase Programme"). The Repurchase Programme is expected to efficiently unlock immediate value for the shareholders of Prosus ("Prosus Shareholders") and Naspers ("Naspers Shareholders"). Prosus will begin sellin

EPPA : New Study Shows That Making Reusable Containers for Takeaway Obligatory Will Undermine the EU’s Environmental Goals27.6.2022 06:00:00 CEST | Press release

Obligatory reusable packaging in takeaway services would be more burdensome for the environment than continuing to use single-use paper-based packaging. This is the conclusion of a new meta-study assessment, commissioned by the European Paper Packaging Alliance and carried out by renowned engineering consultancy, Ramboll. As the European Commission prepares to propose a revision of the Packaging and Packaging Waste Directive (PPWD) with potentially far-reaching implications, the analysis, which examined 26 scientific studies, shows that reuse systems impose exclusive additional burdens to the environment when compared to single-use, related to additional washing, take-back transportation and breakage / unit loss associated with takeaway. The results show that Climate Change is by far the most affected impact category when implementing reuse in take-away services, and that reusable tableware can also have a significant impact on water use. Commenting on the meta-study assessment, Eric L

Teva Announces Promising Interim Results From Its Study PEARL, About the Impact of AJOVY ® (fremanezumab)24.6.2022 18:54:00 CEST | Press release

Teva Pharmaceuticals Europe B.V. today announces promising interim results from its Pan-European Real World study (PEARL), presented for the first time at the European Academy of Neurology (EAN) Congress in Vienna, Austria. The two-year Pan-European Real World (PEARL) prospective, observational study of AJOVY® (fremanezumab), looks at its effectiveness in patients with chronic migraine or episodic migraine, and is an ongoing study sponsored by Teva Pharmaceuticals Europe BV.1 These findings further offer insight into the treatment of migraine in real-world clinical practice. The interim findings were presented by Faisal Mohammad Amin, Associate Professor of Neurology at the University of Copenhagen, Denmark. Out of the total planned 1100 patients in PEARL, 389 patients are included in the interim analysis presented. These findings show that 54.7% of patients in the study had their monthly-migraine-days reduced by 50% or more, over the six-month period from the start of treatment. Addit